Evaluating NALIRIFOX vs Modified Gemcitabine, Nab-Paclitaxel and Cisplatin in Patients With Locally Advanced and Metastatic Pancreatic Adenocarcinoma
Phase 2
52
about 4.1 years
18+
1 site in SC
About this study
Researchers are testing whether NALIRIFOX or a modified treatment (mGAP) is more effective than standard chemotherapy for people with locally advanced or metastatic pancreatic cancer. The trial will last about 1484 days.
Based on ClinicalTrials.gov records.
What participants do
- 1.Take 5-Fluorouracil
- 2.Take Cisplatin
- 3.Take Gemcitabine (mg/m²)
- +3 more
Participation effort
Estimated from trial records. Details can vary by site.
Logistics difficulty varies by site location and availability.
Trial highlights
Treatment details
Auto-extracted from trial records to preview treatments and outcomes.
fluorouracil (Antimetabolite; mimics uracil to disrupt DNA/RNA in cancer cells), cisplatin (Platinum chemotherapy; crosslinks DNA to stop replication), gemcitabine, Antidotes, Deterrents, and Toxicologic Agents (Enzyme Interactions), paclitaxel (Taxane chemotherapy; stabilizes microtubules), oxaliplatin
injection, intravenous, injection (Injection), infusion
Primary: Overall response rate (ORR) assessed by imaging.
Secondary: Best overall response (BOR) assessed by imaging., Disease control rate (DCR)., Duration of response (DOR)., Overall survival (OS)., Progression-free survival (PFS)., Toxicity profile of each chemotherapy regimen.